2025 Q3 -tulosraportti
49 päivää sitten23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
22 013
Myynti
Määrä
5 369
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 131 | - | - | ||
| 5 269 | - | - | ||
| 100 | - | - | ||
| 392 | - | - | ||
| 2 350 | - | - |
Ylin
1,076VWAP
Alin
1,05VaihtoMäärä
0,2 179 988
VWAP
Ylin
1,076Alin
1,05VaihtoMäärä
0,2 179 988
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 179 988 | 179 988 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 179 988 | 179 988 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 15.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2.1.management, management and management,,, there are just not many candidates good enough for those jobs. The skilled Directors must also have skilled people in management and all the way down through the organization, otherwise it won't work. The product, one must understand, has huge potential.
·5 t sittenAnd Happy New Year to you. And I saw your post in Shape yesterday morning, where you mentioned that a loan was to be paid on that day. Perfect timing, a beautiful last warning, for just a few hours later it was too late. What has happened in shape seems more and more shady. If one is to be positive, BP is probably not fraud. Here, both management and many shareholders simply suffer from a lack of realism. Sales are enormous in dreams, but as long as they continue to fail in the real world, the share price will continue to fall, and fall extra much for every new emission... one should probably write unavoidable emission.
·30.12.2025It is under pressure today. Isn't tax-loss selling a big part of the reason? Last chance for 'offsetting', if one has sold other shares with a gain this year. Perhaps there will then be a small rally beginning 2026, provided people want their positions back?·30.12.2025The problem with Bioporto is that there has been tax-loss selling almost daily for all the many years they have been listed on the stock exchange. BP has always lost money... and unfortunately, there's not even a prospect of that changing, and that's why it's falling.
·29.12.2025Any price targets upon approval in usa ?
·29.12.2025How many share issues do you think BP will complete before, if any, the approval comes?
·18.12.2025 · MuokattuCommercial breakthrough Two years after the approval of ProNephro AKI™ (NGAL), it is now possible to purchase the test through Roche Diagnostics. Finally, the test will be included in Roche's catalogs and marketing. For the first two years, sales have been limited to "research use only" From BioPorto's website today (US): "Commercial Availability ProNephro AKI™ (NGAL) – the first FDA-cleared test for AKI risk assessment in ICU patients ≥3 months to <22 years – is now available to order in the US. Integrating a damage biomarker like NGAL into patient assessment can help identify developing and persisting AKI in the 48-72 hours following ICU admission." "Make complex and potentially life-saving care decisions earlier and more confidently." "The First FDA-Cleared Test for Pediatric AKI ProNephro AKI™ (NGAL) for risk assessment – available through Roche Diagnostics." https://bioporto.us/pronephro-aki/·23.12.2025Quite a flop this year, hope the stock gets momentum again.·23.12.2025Keep an eye on the company's development. The price will eventually follow the upward or downward trend.- ·16.12.2025If BP enters KDIGO, how big an increase could one then expect? That is, as an immediate response.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
49 päivää sitten23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2.1.management, management and management,,, there are just not many candidates good enough for those jobs. The skilled Directors must also have skilled people in management and all the way down through the organization, otherwise it won't work. The product, one must understand, has huge potential.·5 t sittenAnd Happy New Year to you. And I saw your post in Shape yesterday morning, where you mentioned that a loan was to be paid on that day. Perfect timing, a beautiful last warning, for just a few hours later it was too late. What has happened in shape seems more and more shady. If one is to be positive, BP is probably not fraud. Here, both management and many shareholders simply suffer from a lack of realism. Sales are enormous in dreams, but as long as they continue to fail in the real world, the share price will continue to fall, and fall extra much for every new emission... one should probably write unavoidable emission.
- ·30.12.2025It is under pressure today. Isn't tax-loss selling a big part of the reason? Last chance for 'offsetting', if one has sold other shares with a gain this year. Perhaps there will then be a small rally beginning 2026, provided people want their positions back?·30.12.2025The problem with Bioporto is that there has been tax-loss selling almost daily for all the many years they have been listed on the stock exchange. BP has always lost money... and unfortunately, there's not even a prospect of that changing, and that's why it's falling.
- ·29.12.2025Any price targets upon approval in usa ?·29.12.2025How many share issues do you think BP will complete before, if any, the approval comes?
- ·18.12.2025 · MuokattuCommercial breakthrough Two years after the approval of ProNephro AKI™ (NGAL), it is now possible to purchase the test through Roche Diagnostics. Finally, the test will be included in Roche's catalogs and marketing. For the first two years, sales have been limited to "research use only" From BioPorto's website today (US): "Commercial Availability ProNephro AKI™ (NGAL) – the first FDA-cleared test for AKI risk assessment in ICU patients ≥3 months to <22 years – is now available to order in the US. Integrating a damage biomarker like NGAL into patient assessment can help identify developing and persisting AKI in the 48-72 hours following ICU admission." "Make complex and potentially life-saving care decisions earlier and more confidently." "The First FDA-Cleared Test for Pediatric AKI ProNephro AKI™ (NGAL) for risk assessment – available through Roche Diagnostics." https://bioporto.us/pronephro-aki/·23.12.2025Quite a flop this year, hope the stock gets momentum again.·23.12.2025Keep an eye on the company's development. The price will eventually follow the upward or downward trend.
- ·16.12.2025If BP enters KDIGO, how big an increase could one then expect? That is, as an immediate response.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
22 013
Myynti
Määrä
5 369
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 131 | - | - | ||
| 5 269 | - | - | ||
| 100 | - | - | ||
| 392 | - | - | ||
| 2 350 | - | - |
Ylin
1,076VWAP
Alin
1,05VaihtoMäärä
0,2 179 988
VWAP
Ylin
1,076Alin
1,05VaihtoMäärä
0,2 179 988
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 179 988 | 179 988 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 179 988 | 179 988 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 15.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
49 päivää sitten23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 15.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2.1.management, management and management,,, there are just not many candidates good enough for those jobs. The skilled Directors must also have skilled people in management and all the way down through the organization, otherwise it won't work. The product, one must understand, has huge potential.·5 t sittenAnd Happy New Year to you. And I saw your post in Shape yesterday morning, where you mentioned that a loan was to be paid on that day. Perfect timing, a beautiful last warning, for just a few hours later it was too late. What has happened in shape seems more and more shady. If one is to be positive, BP is probably not fraud. Here, both management and many shareholders simply suffer from a lack of realism. Sales are enormous in dreams, but as long as they continue to fail in the real world, the share price will continue to fall, and fall extra much for every new emission... one should probably write unavoidable emission.
- ·30.12.2025It is under pressure today. Isn't tax-loss selling a big part of the reason? Last chance for 'offsetting', if one has sold other shares with a gain this year. Perhaps there will then be a small rally beginning 2026, provided people want their positions back?·30.12.2025The problem with Bioporto is that there has been tax-loss selling almost daily for all the many years they have been listed on the stock exchange. BP has always lost money... and unfortunately, there's not even a prospect of that changing, and that's why it's falling.
- ·29.12.2025Any price targets upon approval in usa ?·29.12.2025How many share issues do you think BP will complete before, if any, the approval comes?
- ·18.12.2025 · MuokattuCommercial breakthrough Two years after the approval of ProNephro AKI™ (NGAL), it is now possible to purchase the test through Roche Diagnostics. Finally, the test will be included in Roche's catalogs and marketing. For the first two years, sales have been limited to "research use only" From BioPorto's website today (US): "Commercial Availability ProNephro AKI™ (NGAL) – the first FDA-cleared test for AKI risk assessment in ICU patients ≥3 months to <22 years – is now available to order in the US. Integrating a damage biomarker like NGAL into patient assessment can help identify developing and persisting AKI in the 48-72 hours following ICU admission." "Make complex and potentially life-saving care decisions earlier and more confidently." "The First FDA-Cleared Test for Pediatric AKI ProNephro AKI™ (NGAL) for risk assessment – available through Roche Diagnostics." https://bioporto.us/pronephro-aki/·23.12.2025Quite a flop this year, hope the stock gets momentum again.·23.12.2025Keep an eye on the company's development. The price will eventually follow the upward or downward trend.
- ·16.12.2025If BP enters KDIGO, how big an increase could one then expect? That is, as an immediate response.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
22 013
Myynti
Määrä
5 369
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 131 | - | - | ||
| 5 269 | - | - | ||
| 100 | - | - | ||
| 392 | - | - | ||
| 2 350 | - | - |
Ylin
1,076VWAP
Alin
1,05VaihtoMäärä
0,2 179 988
VWAP
Ylin
1,076Alin
1,05VaihtoMäärä
0,2 179 988
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 179 988 | 179 988 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 179 988 | 179 988 | 0 | 0 |